Immunogenicity of COVID‑19 Vaccines in Lung Cancer Patients: A SOLID Substudy Interim Analysis

Serological Response to SARS-CoV-2 after COVID-19 Vaccination in Lung Cancer patients: Short Review

“…Seven studies included healthy controls (HC) in the study cohorts while two studies [4,28] did not employ controls. Overall, after primary dose vaccination, patients with lung cancer showed lower seropositivity rates compared to healthy controls, and in some cases, a suboptimal response to the vaccine was observed in a certain percentage of lung cancer patients.…”

“…It has also been shown that additional booster doses of the COVID-19 vaccination can improve on the inferior immunological effectiveness of the primary doses in patients with lung cancer. Five studies reported seroconversion rates (defined as the proportion of vaccine recipients whose blood titers for SARS-CoV-2 vaccine antibodies were higher than the test-specific lower limit cutoff value) of LC or thoracic cancer patients, at 93.7% [29], 95.2% [4,30], 98% [30], 99.1% [28], and 96.7% [31,32]. Mack et al [32] reported that LC patient Ab titers had a significantly reduced area under the curve per day compared to control antibody titers.…”

“…One of the largest studies to date, a non-peer-reviewed preprint, is a prospective, longitudinal study conducted in 37 hospitals in Spain. Provencio et al [4] evaluated the immunogenicity of the COVID-19 vaccination in 1,976 LC patients, where 71.4% had adenocarcinoma and 82.6% had active treatment. Two weeks after completion of the primary vaccination doses, 95.2% of LC patients responded to the vaccine with a geometric mean titer of 655.45 BAU/mL (seropositivity SARS-CoV-2 S-RBD IgG cutoff > 7.1 BAU/mL), leaving 4.8% of LC patients with a presumed compromised serological response.…”

Serological Response to SARS-CoV-2 after COVID-19 Vaccination in Lung Cancer Patients: Short Review

“…Seven studies included healthy controls (HC) in the study cohorts, while two studies [ 4 , 28 ] did not employ controls. All studies accounted for the confounding factors of age, anticancer treatment, and steroid use, while most also included performance status and comorbidities [ 4 , 30 , 31 , 32 , 34 , 35 ]. Overall, after primary dose vaccination, patients with lung cancer showed lower seropositivity rates compared to healthy controls.…”

“…In addition, in the early months of the pandemic, there was a substantial decline in cancer screening, which delayed ongoing or planned therapy and increased the risk of poor outcomes [ 3 ]. Earlier reports identified patients with lung cancer (LC) as a vulnerable population to COVID-19 due to their high rates of SARS-CoV-2 infection, more severe course of COVID-19 disease, and predicted fatality rate of more than 30%, especially during the first wave [ 4 , 5 , 6 , 7 ].…”